Neutre
Pfizer's stock remains steady amid legal settlement and 2026 earnings outlook.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
In the past 24 hours, Pfizer's stock has maintained stability as investors digest a new Depo-Provera settlement framework and the company's 2026 earnings guidance. The stock closed at $28.07 on August 21, 2026, with an intraday high of $28.42 and a low of $27.65. The market capitalization stands at approximately $159.97 billion, with a P/E ratio of 36.93.
Points clés
- Pfizer's stock holds steady as investors digest legal settlement and 2026 earnings outlook.
- Pfizer's stock steadies after Q2 2026 beat and modest guidance lift.
- Pfizer declares $0.43 quarterly dividend for third quarter.
Sources
- Pfizer stock holds steady as investors digest legal settlement and 2026 earnings outlook.AD HOC NEWS · August 22, 2026
- Pfizer stock steadies after Q2 2026 beat and modest guidance lift.AD HOC NEWS · August 13, 2026
- Pfizer declares $0.43 quarterly dividend for third quarter.Investing.com · June 24, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
